One hundred patients with classical (52) or definite (48) 
The wide variations in the course of rheumatoid arthritis (RA) make assessment of prognosis uncertain in the early stages of the disease. Some patients will have a brief period of trouble with no or few sequelae, whereas others with a similar presentation will progress inexorably to severe deformity and disability and may even die of the disease, its complications, or its treatment.
From previous follow up studies of RA there has emerged a consensus that life expectancy is reduced, particularly in those with severe arthritis. [1] [2] [3] [4] [5] [6] [7] [8] To some extent the selection of patients for study influences the results: the outcome is more serious when based on hospital inpatients2' and less serious when based on patients with RA identified in population surveys. 5 6 Any cross-sectional analysis based on a rheumatology clinic is likely to overrepresent the more serious cases because many patients with milder arthritis will have been discharged from regular review or never referred in the first place. Prospective long term observation of patients from the early stages of their disease offers the most satisfactory way of assessing the course of the disease, its functional outcome, and its effect on mortality, and of retrospectively testing the value of prognostic indicators in the early stages.
We now report on the 25 year review of such a group of 100 patients with RA. Details of earlier reviews of these patients have already been published.' '2 Patients and methods The 100 patients formed a consecutive series in that all patients referred to JAC with RA of less than a year's duration were accepted into the series if by one year from onset their arthritis met the criteria of the American Rheumatism Association for classical or definite RA. 3 There were 52 patients with classical RA and 48 with definite RA. The mean age of onset for the 100 was 51 years. There were 64 women (mean age of onset 50 years, range 18-81) and 36 men (mean age of onset 52 years, range 22-73) giving a female:male ratio of 1 -8: 1. The mean duration of arthritis when they were first seen was 3 7 months. Previous reviews were made and reported after 11 years, 9 15, 10 18,1 and 20 years. 12 In this 25 year follow up review 35 of the 37 surviving patients were seen and the remaining two were contacted by telephone. In each patient seen a history was taken of previous and current drug treatment and orthopaedic surgery, which will be the subject of a separate report. Physical examination included an assessment of joint score and of functional capacity on the following scale: 1=fit for all activities; 2=moderately restricted; 3=severely restricted; 4= incapacitated.
Blood was taken for cell count and haemoglobin estimation, erythrocyte sedimentation rate (ESR Westergren), and IgM rheumatoid factor. In earlier reviews rheumatoid factor was assessed by the Rose-Waaler test and in this review by a quantitative nephelometric method (Hyland). There is no simple and reliable way to equate results obtained by these two methods.
In an attempt to achieve comparability between them the degree of seropositivity was judged on a four point scale ranging from zero (seronegative) to three (strongly positive) as shown in table 1.
The pattern of the course of the disease in the 35 patients was defined in the following three categories: (a) remitting: initially active RA for up to five years but with no sustained return of active disease thereafter; (b) chronic relapsing: for the 100 patients was 40%. The figure for men was 44% and for women 37%. The difference between these two figures is not significant, indicating that although the death rate among men patients was greater than among women, this did not differ significantly from the greater male mortality expected in the general population. Table 5 shows a comparison between observed Table 7 shows that 26 of the 35 patients were in We found that 12 of the 63 deaths (19%) were directly attributable to RA, and in a further nine (14%) RA was a contributory factor. Thus one third of deaths were related to RA, its complications, or its treatment. This figure is slightly lower than in some previous reports. Constable et al found 44% of deaths to be related to RA,2' Allebeck found 38%,6 and Benn and Wood 50%.22 Our lower figure may be due to our longer follow up period increasing the likelihood of mortality from other causes in an aging population. Table 9 shows the main causes of death in seven published series of patients with RA followed up for periods of nine years or more, 
